720 mcg Vitamin K2 + D3 Ya Rage Kwatancen Hanyoyin Jini ~21 % a Gwajin RCT

Sakamakon da ya fi jan hankali, a sauƙaƙe

Binciken shekaru biyu da aka gudanar a cikin wani gwaji double‑blind, an wallafa a Circulation a shekarar 2026, ya nuna cewa haɗin babban ƙima na vitamin K2 da vitamin D3 na iya rage saurin haɓakar kwatancen hanyoyin jini (coronary artery calcium – CAC) a mutanen da tuni suka samu matuƙar calcium a jijiyoyin coronary. Gwajin DANCODE ya haɗa mutane 400 masu CAC aƙalla 400 Agatston units (AU). An ba su ko touro vitamin K2 + D3 ko placebo tsawon watanni 24, a yanayin double‑blind.

Matsakaicin ƙimar CAC ta ƙaru da 196 AU a ƙungiyar K2 + D3, yayin da ta ƙaru da 248 AU a ƙungiyar placebo. Wannan bambanci na ‑52 AU (95 % CI, ‑79 zuwa ‑24) yana nuni da raguwar kusan 21 % idan aka kwatanta da placebo.

Wannan shi ne babban sakamakon. Sai dai akwai wasu muhimman abubuwan da suka kamata a fahimta – za mu tattauna su a ƙasa.

Abin da binciken ya ƙunshi a zahiri

DANCODE gwaji ne na ƙasashe da dama, double‑blind kuma placebo‑controlled. An ɗauki mahalarta daga Fabrairu 2023 zuwa Fabrairu 2024. Mahimman bayanai:

• Mahalarta: 398 da aka yi nazari a kansu (30 % mata), tsaka‑tsakin shekaru 71, tsaka‑tsakin CAC = 903 AU a farkon. Kusan 44 % na su suka kai ko sun wuce 1000 AU.
• Abun da aka ba: Vitamin K2 720 μg a kowace rana tare da vitamin D3 25 μg (1 000 IU) a kowace rana, ko placebo.
• Tsawon lokacin bincike: watanni 24, tare da CT na zuciya a farkon, bayan watanni 12, da kuma a watanni 24.
• Manufa ta farko: canjin ƙimar CAC a watanni 24, an yi nazari bisa ga “intention‑to‑treat”.
• Rijista: ClinicalTrials.gov NCT05500443.

Tasirin ya kasance daidaito a duk jinsuna, kuma a cikin rukuni biyu na CAC na farko (400‑999 AU da 1000 AU ko fiye).

Dalilin da ke sanya ci gaban CAC mahimmanci

CAC ma'auni ne da ake amfani da shi sosai wajen auna adadin plaque mai calcium a jijiyoyin coronary. Saurin ci gaban CAC yana da alaƙa da ƙaruwa a haɗarin cututtukan zuciya, don haka ana amfani da shi a matsayin alamar wakili a fannin kardiology. A halin yanzu, babu wani abu da aka tabbatar da iya rage wannan ci gaba sai an sarrafa haɗarin asali. Statins, misali, suna rage haɗarin kardiovaskular, amma sau da yawa suna haifar da ƙaruwa a adadin calcium a plaque yayin da plaque ke ƙarfafa.

Vitamin K, musamman matrix‑Gla protein, yana taimakawa wajen rage taruwar calcium a bangon jijiyoyi – shi ne tushen kimiyyar gwajin K2. DANCODE babban gwaji ne da ya gwada wannan zato a cikin al’umma masu cutar coronary mai tsanani.

Sakamakon yanayin plaque

Wani damuwa mai tasiri ga duk wani maganin calcium shi ne ko zai canza yanayin plaque daga na ƙarfi (calcified) zuwa marar ƙarfi (non‑calcified). Plaque mai calcified ana ɗauka a matsayin mafi dindindin fiye da plaque marar calcified.

Don nazarin wannan, an yi CT‑angiography a kan mahalarta 143 (CAC < 1000 AU) a farkon da bayan watanni 24. Sakamakon:

• Jimillar yawan plaque ya ƙaru a duka ƙungiyoyi.
• Yawan plaque marar calcified ba ya nuna bambanci tsakanin ƙungiyoyi, don haka babu alamar cewa calcium ya tashi ya ƙara plaque marar calcified.
• Yawan plaque calcified ya ragu a ƙungiyar K2 + D3 da bambanci na ‑8 mm³ (95 % CI, ‑13 zuwa ‑2).

Rubutattun masu bincike sun kammala da cewa raguwar ci gaban calcification ba ta da alaƙa da karuwar plaque marar calcified – alamar kwanciyar hankali, amma aiyukan da suka samu a wannan ɓangare ƙarami ne, kuma tazara a CI ya yi fadi sosai.

Ku kasance masu gaskiya game da abubuwan da ba a nuna ba

Sakamakon yana da ƙarfi, amma akwai iyakoki da ya kamata a sani:

• Ya rage ci gaba; ba ya mayar da calcium. Duk ƙungiyoyi sun ci gaba da ƙara calcium. Rukuni na K2 + D3 ya samu matsakaicin ƙaruwa 196 AU, don haka maganin ya rage saurin ƙara amma ba ya cire waɗanda suka riga suka taru.
• Babu bayanan lamuran likita. Babban burin binciken shine hoton CAC. Ba a tsara shi ko rahoto don auna adadin bugun zuciya, shigar da magani, ko mutuwa ba. Ba a san ko bambancin 52 AU a cikin shekaru biyu zai haifar da raguwar lamuran kardiovaskular ba.
• Mahalarta manya, masu haɗari sosai. Tsaka‑tsakin shekaru 71, duk suna da CAC mai tsanani. Sakamakon na iya rashin dacewa ga matasa, ko ga waɗanda ke da CAC ƙasa ko babu.
• Bibiya na tsawon shekaru biyu kacal. Za a buƙaci ƙarin gwaje‑gwaje na dogon lokaci don tantance ko tasirin zai ci gaba da rage ko zai ɓace.
• Haɗin K2 da D3. An ba su tare, don haka ba a iya tantance wane ɓangare ne ya ba da mafi yawan tasiri ba.

Wane samfur aka yi amfani da shi?

Takaitaccen bayanin ba ya ambaton wani samfur na kasuwanci. Rahoton masana'antu daga NutraIngredients ya nuna cewa K2 da aka yi amfani da shi shi ne Balchem's K2VITAL, nau'in menaquinone‑7 (MK‑7). Wannan bayani ne kawai a cikin rahoton, ba a nuna a cikin takardar ba, don haka ku duba sashen hanyoyin a takardar asali don cikakken bayani. Sakamakon daga wannan ƙima ba za a ɗauke shi a matsayin gaba ɗaya ga duk wani samfurin K2 ba, musamman waɗanda ke da ƙima ƙasa da na OTC.

Abubuwan da za a iya amfani da su a aikace

• Dosage da aka gwada: 720 μg K2 + 25 μg (1 000 IU) D3 a kowace rana. Wannan ya fi yawan K2 da ke cikin yawancin multivitamins da ƙwayoyin kari.
• Wanene zai iya amfana: manya masu tsanani da CAC mai yawa, mafi alheri a ƙarƙashin kulawar ƙwararren likitan zuciya. Ba a nuna cewa mutanen da CAC ya ƙasa ko babu za su amfana ba.
• Ba maye gurbin magunguna. Matsin jini, LDL‑cholesterol, suga a jini, daina shan taba, da magungunan da aka rubuta su ne ginshiƙan rigakafin cutar zuciya.
• Tattaunawa da likita kafin a haɗa da warfarin ko maganin anticoagulant. Vitamin K yana shafar yadda waɗannan magungunan ke aiki; canjin yawan shan K2 na iya tasiri kan INR. Kada ku fara ƙarin K2 ba tare da kulawar likita da sa ido kan INR ba.
• Nemi shawarar ƙwararre idan kuna da cutar ƙoda, kuna shan anticoagulant, ko kuna da wasu yanayi masu rikitarwa.

Kammalawa

DANCODE daga cikin mafi ƙarfi hujjojin da ke nuna cewa haɗin vitamin K2 da D3 na iya rage alamar hoto mai ƙarfi ta cutar coronary, tare da tasiri daidaito a rukuni‑rukuni kuma ba tare da ƙaruwa a plaque marar calcified ba. Amma maganin ya rage ƙaruwa a calcium a ƙungiyar manya, ba ya mayar da calcium da aka riga aka tara, kuma ba a tabbatar da fa'idar lafiyar da ke tafe ba. Tambayoyi na gaba sun haɗa da ko tasirin zai daɗe, ko zai rage ainihin lamuran kardiovaskular, da kuma ko K2 kai‑kai ke da tasiri. Har sai an sami ƙarin shaida, wannan ƙarin zai iya zama na taimako a tattaunawa tare da likitan zuciya, ba a matsayin maye gurbin magungunan da aka tabbatar da tasiri ba.

Source: Hasific et al., Circulation (2026), PMID 42661461, DOI 10.1161/CIRCULATIONAHA.126.082363.